T saidhere is another new drug that is starting to spread rapidly through the United States street drug supply: Xylazine, an animal sedative, widely used as a synthetic inhibitor for opioids like heroin. We republished a study, based on years of research across the US, which found that xylazine is growing in cities around the country. Drug use is increasing at exponential rates where it lands, leading to skin diseases and overdoses.
The prevalence of xylazine poses a threat to public health. It foretells the future of the overdose problem – it will be greatly exacerbated by strong synthetic compounds combined into strong synthetic compounds.
Xylazine is not self -evident. Instead, it is often combined with other types of drugs that contain fentanyl – a family of potent opioids produced in underground labs. Over the past 10 years, synthetically produced fentanyl has been largely brought to the illicit opioid market that was previously dominated by farm -produced heroin; Fentanyl may be more potent than heroin in weight.
Combined with the negative effects found in hidden supply chains, this has started the deadliest overdose problem in recorded history. The U.S. death toll is more than twice the second highest country (TK), and nearly 20 times the world average. Consumers were drawn to fentanyl for its potent psychoactive effects. But fentanyl is very short -acting, and keeping the appetite at the beach may require ingestion five or six times a day, rather than two or three if using the heroin. That means often looking for a safe, getting a clean syringe, and worrying about an overdose problem. That’s the minimum time between injections to maintain basic needs. And it increases the risk of injection -related health conditions, such as infections and varicose veins.
This is where xylazine comes in: it enhances the effect of fentanyl – or, while this is often put on the road, it “gives the legs.” The addition of xylazine to a supplement can delay cravings and both return symptoms for the duration of fentanyl alone.
Its problems, however, are many. Xylazine is a sedative. At higher altitudes, he does not see the people. Instead of the semi-arousal euphoria of opioids, people taking fentanyl supplemented with xylazine may darken and wake up hours later. In the short term, users of this type of medication are more likely to be injured, abused, or hit by cars, for example.
The effect of xylazine increases the risk of overdose. Worse, naloxone (primary response to overdoses) does not convert, because it is not an opioid.
Many medical users, as well as doctors and advocates of risk reduction, recommend xylazine to relieve skin lesions in a dangerous way. There have also been some reports of xylazine being the cause of foreign blood, with users reporting to the hospital with low blood pressure counts.
But xylazine isn’t the only synthetic substance that is spreading through pharmaceuticals. Fentanyl’s move to heroin has started a wave of new synthetic additives. Newer benzodiazepines, opioids (such as “nitazenes,”) stimulants, cannabinoids, and sedatives are coming out at an alarming rate. With many underground labs producing fentanyl, the starting cost for synthesizing other additives is low. And the unregulated road markets force lab tests to be an endless competition to combine and compare new synthetic techniques to see which companies perform best.
Novel synthetics poses many logistical problems for the evaluation of the drug. Underfunded medical researchers seek to continue the constant changes of synthetic drugs that lead to overdose death. In fact, health officials and the government in the U.S. have little idea of the true nature and abundance of synthetic drugs today.
Many of these substances actually appeal to consumers because, like xylazine, they degrade fentanyl. The combination of drugs also increases the psychoactive effects, which makes the use of the drug more pleasant. At the same time, synthetic drugs appeal to pharmaceutical manufacturers and consumers. They offer low -cost ways to produce high -quality products and allow them to increase market share and revenue through independent methods.
Despite the health risks from these, there are important market aspects for them, confirming their proliferation. In the U.S. nonprofit drug markets, there will always be a supply to meet the requirements. The legacy of fentanyl has taught us that trying to limit the supply of dangerous synthetics through the police is costly and almost endless.
But new technologies need to be implemented to encourage drug consumers to make safer choices.
A very promising way can be found with full medical screening services. Users can take their medications into the emergency rooms for a quick test, then walk away after 10 minutes with a full list. Like grocers with food labels, they can see the compounds and how much they are eating.
The movement of fentanyl into medicines has been shown to vary widely, even from the consumer. Seeing these movements on a daily basis can save lives. Some toxic substances, such as xylazine, can be prevented. When consumers know that xylazine is available, and in a sense, they can create market demand for xylazine -safe products.
Pain reduction programs are available across the country, and they help people who use drugs stay safe, by doing things like donating sterile syringes and naloxone. Instead, they need federal funding, funding, and training to open up full -time medical screening services. There are currently very few of these programs in the United States, although the technology required to use them has been available and readily available in recent years.
The nation has prospered in a few different ways of looking at medicine. For example, fentanyl test units can detect the drug in pills, tablets, and injectable formulations, but they only tell the user if fentanyl is present and not available – not the drugs. Navigation bar. These pieces are suitable for casual users of non-opioid medications.
Another important strategy to reduce the risk is to replace a poisonous drug with a safe one. This is seen in the heroin prescription programs, which have been used for many years in Europe with great success. During these programs, nurses provide a safe course of heroin – morning and night, free of charge. Under these conditions, an overdose is almost impossible. Instead of spending the rest of the day raising money to buy expensive street heroin, users can spend their time working, living with their family, or exploring. Doing other things to improve their lives. In this way, many people gain the resilience they need to resist their demons and overcome the usual circles of exploitation that they will no longer be happy. These programs are more effective than methadone programs in helping to achieve heroin abstinence. It may seem like an objection, but giving people the medications they are looking for is the best way to help them deal with personal problems and quit those medications.
In fact, the scrutiny of drug and heroin programs faces serious political scrutiny from those interested in police / prisons. But years of evidence show us that we can’t catch our way out of the growing overdose problem.
Ten years ago, it was an opportune time to respond to the fentanyl export market. Now, while xylazine and other manufacturers are spreading across the country in their shade, we have another opportunity to use solutions related to evidence in the face of the crisis of the deadliest drug in recorded history.
Must Read Stories from TIME